Horizon launches cfDNA reference standard
March 10, 2017—Horizon Discovery Group launched its first HDx cfDNA (cell-free DNA) reference standard in synthetic plasma.
cfDNA-based diagnostics are at a particularly high risk of error, and an assay may be required to identify as few as 50 copies of a target sequence that has already undergone DNA damage. This is further complicated by the amount of cfDNA present in a sample being highly variable patient to patient.
Laboratories must therefore extract and reliably quantify as much cfDNA as possible. Horizon’s new multiplex I cfDNA reference standard set in synthetic plasma directly addresses this problem by allowing users to control for the entirety of their workflows, from sample extraction to result reporting, interrogating the sources of variability at each step so they can address them.
Developed using clinically relevant mutations, the Multiplex I cfDNA Reference Standard Set in Synthetic Plasma contains eight cancer-relevant mutations including BRAF, EGFR, KRAS, NRAS, and PIK3CA at five percent, one percent, and 0.1 percent allelic frequencies (RUO only).